Economic growth begins with ideas, innovation and creativity. Since the signing of the Constitution, the U.S. has protected the fruits of creativity and innovation through intellectual property protection, primarily expressed as patents, trademarks, copyright and trade secrets.
As our economy has become even more dependent on innovation, intellectual property issues have been pushed to the forefront. The clashes have led some to question the value and even the legitimacy of IP protection. While some of these attacks come from the libertarian perspective, most originate from the same naïve socialist impulses that so demonstrably failed in the realm of real property—but somehow are seen as thoughtful with respect to IP.
IPI believes that creators have the right to own and control the fruits of their creativity, and that the IP system has done an admirable job of not only incentivizing innovation, but also making creative products and services available to the public and transferring technology to the developing world.
Only immediate attention from the White House can prevent WIPO from becoming dominated by China, which would pose risks to the entire global IP system, and thus to U.S. security and innovation.
Governments can't act as quickly as private sector drug companies when it comes to finding a vaccine for the coronavirus or any other epidemic.
You’re served with a notice. Apparently you’d shared some photos you didn’t own on the internet a while ago, and now someone–possibly an artist, possibly a copyright troll–can file for damages of up to $30,000. Scam, you think, and toss the paper. Unfortunately for you, those copyright infringement proceedings were real, and now a government entity unbeknownst to you–something called the Copyright Claims Board–has determined, without judge or jury, that you owe this person $30,000.
The licensing of intellectual property is put at risk by absurd outcomes like the HouseCanary verdict.
The U.S economy is losing $12.5 billion annually to music theft, reports IPI.
Coalition Letter Expressing Concerns with S.1416, the "Affordable Prescriptions for Patients Act of 2019"
Coalition of conservative & free-market groups express concern with S.1416, the Affordable Prescriptions for Patients Act of 2019, as introduced by Sen. John Cornyn (R-TX) and Richard Blumenthal (D-CT).
Senators John Cornyn and Richard Blumenthal want to control prescription drug prices by empowering bureaucracy. When has that ever worked?
Sen. John Cornyn's legislation that attempts to address problems he sees with the patent protections afforded to American drug companies overreaches and would limit the ability of pharmaceutical firms to develop and improve medicines.